Literature DB >> 26862168

Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation.

Todd A Triplett1, Kim T Cardenas1, Jessica N Lancaster1, Zicheng Hu1, Hilary J Selden1, Guadalupe J Jasso1, Sadhana Balasubramanyam1, Kathy Chan1, LiQi Li2, Xi Chen3, Andrea N Marcogliese4, Utpal P Davé5, Paul E Love2, Lauren I R Ehrlich6.   

Abstract

Primary T-cell acute lymphoblastic leukemia (T-ALL) cells require stromal-derived signals to survive. Although many studies have identified cell-intrinsic alterations in signaling pathways that promote T-ALL growth, the identity of endogenous stromal cells and their associated signals in the tumor microenvironment that support T-ALL remains unknown. By examining the thymic tumor microenvironments in multiple murine T-ALL models and primary patient samples, we discovered the emergence of prominent epithelial-free regions, enriched for proliferating tumor cells and dendritic cells (DCs). Systematic evaluation of the functional capacity of tumor-associated stromal cells revealed that myeloid cells, primarily DCs, are necessary and sufficient to support T-ALL survival ex vivo. DCs support T-ALL growth both in primary thymic tumors and at secondary tumor sites. To identify a molecular mechanism by which DCs support T-ALL growth, we first performed gene expression profiling, which revealed up-regulation of platelet-derived growth factor receptor beta (Pdgfrb) and insulin-like growth factor I receptor (Igf1r) on T-ALL cells, with concomitant expression of their ligands by tumor-associated DCs. Both Pdgfrb and Igf1r were activated in ex vivo T-ALL cells, and coculture with tumor-associated, but not normal thymic DCs, sustained IGF1R activation. Furthermore, IGF1R signaling was necessary for DC-mediated T-ALL survival. Collectively, these studies provide the first evidence that endogenous tumor-associated DCs supply signals driving T-ALL growth, and implicate tumor-associated DCs and their mitogenic signals as auspicious therapeutic targets.

Entities:  

Keywords:  IGF1R; T-ALL; dendritic cell; leukemia; tumor microenvironment

Mesh:

Substances:

Year:  2016        PMID: 26862168      PMCID: PMC4776467          DOI: 10.1073/pnas.1520245113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  62 in total

1.  Production and characterization of immature murine T-lymphoma cell lines.

Authors:  E R Richie; D A Walker
Journal:  Methods Mol Biol       Date:  2000

2.  novoSNP, a novel computational tool for sequence variation discovery.

Authors:  Stefan Weckx; Jurgen Del-Favero; Rosa Rademakers; Lieve Claes; Marc Cruts; Peter De Jonghe; Christine Van Broeckhoven; Peter De Rijk
Journal:  Genome Res       Date:  2005-03       Impact factor: 9.043

3.  BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR.

Authors:  Joan M Carboni; Mark Wittman; Zheng Yang; Francis Lee; Ann Greer; Warren Hurlburt; Stephen Hillerman; Carolyn Cao; Glenn H Cantor; Janet Dell-John; Cliff Chen; Lorell Discenza; Krista Menard; Aixin Li; George Trainor; Dolatrai Vyas; Robert Kramer; Ricardo M Attar; Marco M Gottardis
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

4.  T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell.

Authors:  Thomas Serwold; Konrad Hochedlinger; John Swindle; Joe Hedgpeth; Rudolf Jaenisch; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

5.  Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia.

Authors:  Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Lancet Oncol       Date:  2009-01-13       Impact factor: 41.316

6.  Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth.

Authors:  Ada Girnita; Leonard Girnita; Fabrizio del Prete; Armando Bartolazzi; Olle Larsson; Magnus Axelson
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

7.  IGF-IR tyrosine kinase interacts with NPM-ALK oncogene to induce survival of T-cell ALK+ anaplastic large-cell lymphoma cells.

Authors:  Ping Shi; Raymond Lai; Quan Lin; Abid S Iqbal; Leah C Young; Larry W Kwak; Richard J Ford; Hesham M Amin
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

8.  Thymic epithelial cells promote survival of human T-cell acute lymphoblastic leukemia blasts: the role of interleukin-7.

Authors:  Maria T Scupoli; Fabrizio Vinante; Mauro Krampera; Carlo Vincenzi; Gianpaolo Nadali; Francesca Zampieri; Mary A Ritter; Efrem Eren; Francesco Santini; Giovanni Pizzolo
Journal:  Haematologica       Date:  2003-11       Impact factor: 9.941

9.  Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage.

Authors:  Matthew M Meredith; Kang Liu; Guillaume Darrasse-Jeze; Alice O Kamphorst; Heidi A Schreiber; Pierre Guermonprez; Juliana Idoyaga; Cheolho Cheong; Kai-Hui Yao; Rachel E Niec; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2012-05-21       Impact factor: 14.307

10.  Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation.

Authors:  E Deutsch; L Maggiorella; B Wen; M L Bonnet; K Khanfir; V Frascogna; A G Turhan; J Bourhis
Journal:  Br J Cancer       Date:  2004-11-01       Impact factor: 7.640

View more
  9 in total

1.  Function of insulin-like growth factor 1 receptor in cancer resistance to chemotherapy.

Authors:  Jingsheng Yuan; Zhijie Yin; Kaixiong Tao; Guobing Wang; Jinbo Gao
Journal:  Oncol Lett       Date:  2017-10-26       Impact factor: 2.967

2.  Physiologic IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia.

Authors:  Leonardo Luís Artico; Angelo Brunelli Albertoni Laranjeira; Livia Weijenborg Campos; Juliana Ronchi Corrêa; Priscila Pini Zenatti; José Barreto Campello Carvalheira; Sandra Regina Brambilla; Alexandre Eduardo Nowill; Silvia Regina Brandalise; José Andrés Yunes
Journal:  Blood Adv       Date:  2021-09-28

Review 3.  Early T-cell precursor lymphoblastic leukemia accompanied by prominent blastic plasmacytoid dendritic cell proliferation mimicking blastic plasmacytoid dendritic cell neoplasm: an exceptional case report and literature review.

Authors:  Nenggang Jiang; Qin Zheng; Hongyan Liao; Jiang Yu; Yu Liu; Sha Zhao; Huanling Zhu; Dongsheng Xu
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-06       Impact factor: 4.322

4.  Molecular pathway activation features of pediatric acute myeloid leukemia (AML) and acute lymphoblast leukemia (ALL) cells.

Authors:  Ivan Petrov; Maria Suntsova; Olga Mutorova; Maxim Sorokin; Andrew Garazha; Elena Ilnitskaya; Pavel Spirin; Sergey Larin; Olga Kovalchuk; Vladimir Prassolov; Alex Zhavoronkov; Alexander Roumiantsev; Anton Buzdin
Journal:  Aging (Albany NY)       Date:  2016-11-19       Impact factor: 5.682

Review 5.  Therapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update.

Authors:  Camilla Evangelisti; Francesca Chiarini; James A McCubrey; Alberto M Martelli
Journal:  Int J Mol Sci       Date:  2018-06-26       Impact factor: 5.923

Review 6.  Insulin-like growth factor receptor signaling in tumorigenesis and drug resistance: a challenge for cancer therapy.

Authors:  Hui Hua; Qingbin Kong; Jie Yin; Jin Zhang; Yangfu Jiang
Journal:  J Hematol Oncol       Date:  2020-06-03       Impact factor: 17.388

7.  Single-cell map of diverse immune phenotypes in the acute myeloid leukemia microenvironment.

Authors:  Rongqun Guo; Mengdie Lü; Fujiao Cao; Guanghua Wu; Fengcai Gao; Haili Pang; Yadan Li; Yinyin Zhang; Haizhou Xing; Chunyan Liang; Tianxin Lyu; Chunyan Du; Yingmei Li; Rong Guo; Xinsheng Xie; Wei Li; Delong Liu; Yongping Song; Zhongxing Jiang
Journal:  Biomark Res       Date:  2021-03-01

8.  Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies.

Authors:  Valentina Cordo'; Mariska T Meijer; Rico Hagelaar; Richard R de Goeij-de Haas; Vera M Poort; Alex A Henneman; Sander R Piersma; Thang V Pham; Koichi Oshima; Adolfo A Ferrando; Guido J R Zaman; Connie R Jimenez; Jules P P Meijerink
Journal:  Nat Commun       Date:  2022-02-25       Impact factor: 17.694

Review 9.  A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation.

Authors:  Marta Surbek; William Tse; Richard Moriggl; Xiaonan Han
Journal:  Cytokine       Date:  2021-01-19       Impact factor: 3.861

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.